Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 Holistic benefit: secondary endpoints showed significant and clinically meaningful improvements...
Hence then, the article about ucb presents positive results from gemz phase 3 study at aes showing fenfluramine significantly reduces countable motor seizure frequency in cdkl5 deficiency disorder was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder )
Also on site :
- Congress passes war powers measure for first time, rebuking Trump's war with Iran
- Olympic gold medalist Haley Winn visits Plank Road South Elementary in Webster
- Best Prime Day 2026 Tech Deals Under $100: Save Up to 75% on Bose, Beats by Dre, Samsung & Other Top Brands